Clinical trials: Nonsmall Cell Lung Cancer, Stage II
NSCLC Stage IV
SBRT for Oligo-residual NSCLC After Treatment With PD-1/PD-L1 Immune Checkpoint Inhibitors
Despite the impressive response rate to PD-1/PD-L1 immune checkpoint inhibitors, resistance inevitably develops in most patients.
- Trial name
- NCT04767009
- Testing
- PD-1/PD-L1 inhibitors (alone or in combination with chemotherapy), SBRT
- Where
- China
- Volunteers
- 59 people
- Sponsor
- Fudan University
Lung Cancer, Nonsmall Cell
Evaluating Crizotinib in the Neoadjuvant Setting in Patients With Non-small Cell Lung Cancer
This study will evaluate the efficacy of crizotinib as induction therapy in participants with surgically resectable ALK rearrangement, ROS1 rearrangement, or MET exon 14 mutation positive NSCLC.
- Trial name
- NCT03088930
- Testing
- Crizotinib
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Colorado, Denver
Lung Cancer
Docetaxel and Thalidomide as Second-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00114192
- Testing
- docetaxel, thalidomide
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- University of Virginia
Non-Small Cell Lung Cancer, Nonsmall Cell Lung Cancer
Pacritinib in Patients With Endothelial Growth Factor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC) After EGFR Tyrosine Kinase Inhibitor (TKI)
The goal of the study is to find the best dose of pacritinib when given in combination with erlotinib.
- Conditions
- Non-Small Cell Lung Cancer, Nonsmall Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung
- Trial name
- NCT02342353
- Testing
- Pacritinib, Erlotinib
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Washington University School of Medicine
Carcinoma, Non-Small-Cell Lung
The 'MADe IT' Clinical Trial: Molecular Analyses Directed Individualized Therapy for Advanced Non-Small Cell Lung Cancer
The standard treatment for non-small cell lung cancer, stage IV or IIIB malignant pleural effusion is chemotherapy. The decision to use a regimen is currently determined by toxicity or by physician's preference.
- Trial name
- NCT00215930
- Testing
- Vinorelbine, Docetaxel, Gemcitabine
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Non-small Cell Lung Cancer
Three Modalities of Treatment in Operable and Resectable Stage IIIA (T1-3, N2) Non-Small Cell Lung Cancer (NSCLC)
Stage IIIA non-small cell lung cancers comprising a mediastinal ganglionic invasion N2 account for 20 to 30% of the NSCLCs. They are almost always potentially resectable, but the results obtained by surgery alone or surgery…
- Trial name
- NCT00198367
- Testing
- Cisplatin-Gemzar, Cisplatin-Navelbine-Radiotherapy, Carboplatin-Taxol-Radiotherapy
- Where
- France
- Volunteers
- 120 people
- Sponsor
- Hospices Civils de Lyon
Breast Cancer, Lung Cancer
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
RATIONALE: Gathering information about how often osteonecrosis of the jaw occurs in patients receiving zoledronic acid for bone metastases may help doctors learn more about the disease and provide the best follow-up care.
- Conditions
- Breast Cancer, Lung Cancer, Metastatic Cancer, Multiple Myeloma
- Trial name
- NCT00874211
- Testing
- assessment of therapy complications
- Where
- 453 sites in United States, Mexico and 1 more
- Volunteers
- 3,571 people
- Sponsor
- SWOG Cancer Research Network
Non-small Cell Lung Cancer, Non-small Cell Carcinoma
Combining ICI With SBRT or HypoFrx-RT for ES NSCLC
This study will explore the best dose of radiation to be used when treating stage I-III non-small cell lung cancer (NSCLC) with stereotactic body radiation therapy (SBRT) or hypo-fractionated radiotherapy (HypoFrx-RT) that is…
- Conditions
- Non-small Cell Lung Cancer, Non-small Cell Carcinoma, Non-small Cell Lung Cancer Stage I, Non-small Cell Lung Cancer Stage II
- Trial name
- NCT05451173
- Testing
- Stereotactic body radiotherapy, Hypofractionated radiotherapy, Durvalumab
- Where
- China
- Volunteers
- 83 people, healthy volunteers welcome
- Sponsor
- Alexander Chi
Lung Cancer Stage III
Neoadjuvant IBI308, Bevacizumab, Plus Pemetrexed and Carboplatin Followed by Surgery in Unresectable Stage III NSCLC
The purpose of this study is to studying neoadjuvant IBI308, bevacizumab, plus pemetrexed and carboplatin followed by surgery to see how well it works in treating patients with unresectable stage III non-small cell lung cancer.
- Trial name
- NIBCUN (NCT03872661)
- Testing
- IBI308, Bevacizumab, Pemetrexed
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Sun Yat-sen University
Non Small Cell Lung Cancer, Respiratory Tract Neoplasm
Study for Evaluating the Safety and Feasibility of Fecal Microbiota Transplant in Stage II-III NSCLC Patients Using ICI Responders as Donors (MIGRANT)
This is a randomized, phase II, multi-centre clinical trial. Sample size: 68 patients (Experimental Arm (Durvalumab + chemotherapy + FMT capsules): 34 patients, Control Arm (Durvalumab + chemotherapy): 34 patients) Population…
- Trial name
- MIGRANT (NCT07247786)
- Testing
- Biological: Fecal Microbiota Transplantation, Durvalumab, Paclitaxel
- Where
- 20 sites in Spain
- Volunteers
- 68 people
- Sponsor
- Fundación GECP
Non-small Cell Lung Cancer, Stage III
Abraxane and RT for Non-Small Cell Lung Cancer (NSCLC)
For patients with stage III Lung Cancer, We propose one cycle chemotherapy using Abraxane and Carboplatin, followed by pulsed low-dose sensitizing Abraxane chemotherapy and daily Radiation.
- Trial name
- NCT00903942
- Testing
- radiation therapy, Paclitaxel Protein-Bound, and CARBOPLATIN
- Where
- United States
- Sponsor
- University of Rochester
Bladder Cancer, Breast Cancer
Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Colony-stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or…
- Conditions
- Bladder Cancer, Breast Cancer, Carcinoma of Unknown Primary, Esophageal Cancer
- Trial name
- NCT00014456
- Testing
- filgrastim, docetaxel, gemcitabine hydrochloride
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
NSCLC Stage IV, EGFR Gene Mutation
Osimertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR Mutant NSCLC (STEREO)
STEREO is single-arm phase II study, which aims to evaluate the safety and efficacy of osimertinib combined with early locally ablative radiotherapy of all cancer sites in patients with synchronous oligo-metastatic (primary…
- Trial name
- STEREO (NCT04908956)
- Testing
- Osimertinib, Stereotactic Body Radiation Therapy (SBRT)
- Where
- 18 sites in Italy, Netherlands and 6 more
- Volunteers
- 6 people
- Sponsor
- ETOP IBCSG Partners Foundation
Lung Cancer
Carboplatin, Gemcitabine, and Thalidomide in Patients Undergoing Surgery for Stage II or III Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as carboplatin and gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00281827
- Testing
- carboplatin, gemcitabine hydrochloride, thalidomide
- Where
- 3 sites in United States
- Volunteers
- 22 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Non Small Cell Lung Cancer
Neoadjuvant Durvalumab/Anlotinib /Chemotherapy Plus Curative Resection in Stage III Non-Small-Cell Lung Cancer : A Single-arm Phase II Study
This is a randomized, open label study designed to evaluate the efficacy and safety of neoadjuvant Durvalumab/Anlotinib/Chemotherapy followed by surgery in resectable stage III non-small cell lung cancer.
- Trial name
- NCT04762030
- Testing
- Durvalumab Anlotinib Carboplatin Nab-paclitaxel
- Where
- China
- Volunteers
- 39 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Lung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC v8
Quality of Life Intervention to Inform Patient Decision-Making in Early-Stage Lung Cancer
This clinical trial studies the effect of a quality of life intervention on decision-making in patients with early-stage lung cancer who are undergoing standard of care surgery or stereotactic body radiation therapy (SBRT).
- Conditions
- Lung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage IA1 Lung Cancer AJCC v8, Stage IA2 Lung Cancer AJCC v8
- Trial name
- NCT05292521
- Testing
- Best Practice, Informational Intervention, Questionnaire Administration
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Roswell Park Cancer Institute
Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer Stage II
A Study of Trastuzumab Deruxtecan in People With Non-Small Cell Lung Cancer
The purpose of this study is to find out how many people with HER2-amplified or HER2-mutated non-small cell lung cancer (NSCLC) experience a decrease in tumor viability when they receive trastuzumab deruxtecan before routine…
- Conditions
- Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer Stage II, Non-Small Cell Lung Cancer Stage IIIA, Non-Small Cell Lung Cancer Stage IIIB
- Trial name
- NCT07428044
- Testing
- Trastuzumab Deruxtecan
- Where
- 10 sites in United States, Canada
- Sponsor
- Memorial Sloan Kettering Cancer Center
Non-Small Cell Carcinoma of Lung, TNM Stage 4
Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC
While cigarette smoking remains the primary cause of most lung cancer cases, lung carcinoma in never smokers account for nearly 20 percent of cases.
- Trial name
- NCT03786692
- Testing
- Arm A, Arm B
- Where
- United States
- Volunteers
- 107 people
- Sponsor
- Fox Chase Cancer Center
Non-small Cell Lung Cancer
A Clinical Study of Immunotherapy Combined With Chemotherapy and Anti-angiogenic Therapy in Operable NSCLC
The objective of this prospective, single-arm, single-center clinical study is to evaluate the efficacy and safety of envafolimab combined with platinum-containing dual-drug chemotherapy and recombinant human endostatin regimens…
- Trial name
- NCT05360979
- Testing
- envafolimab
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Second Xiangya Hospital of Central South University
Non-Small Cell Lung Cancer
Efficacy and Safety Study of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Adults With Unresected Stage I or II Non-Small Cell Lung Cancer (NSCLC) (MK-3475-867/KEYNOTE-867)
The purpose of this study is to assess the efficacy and safety of stereotactic body radiotherapy (SBRT) plus pembrolizumab (MK-3475) in the treatment of adult participants with unresected Stage I or II (Stage IIB N0, M0)…
- Trial name
- NCT03924869
- Testing
- Stereotactic Body Radiotherapy (SBRT), Pembrolizumab
- Where
- 194 sites in United States, Argentina and 22 more
- Volunteers
- 448 people
- Sponsor
- Merck Sharp & Dohme LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.